Global Injectable Drug Delivery Devices Market
Research Report: Information by Devices (Conventional Injection Devices and
Self-Injection Devices), Therapeutic Application (Autoimmune Diseases, Hormonal
Disorders and Cancer), Usage Pattern (Curative pattern and Immunization), Site
of Delivery (Intramuscular, Subcutaneous and Intra Dermal), Distribution
Channel (Hospital & Retail Pharmacies and Online Platforms), Facility of
Use (Hospitals and Clinics and Home Care Settings) and Region (Americas,
Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2023
Market scenario:
The Global Injectable Drug Delivery Devices Market is expected to
register 11.3% CAGR and is anticipated to reach USD 17,401.8 million by 2023.
Injectable drug delivery devices, including conventional syringes, needle-free
injectors, and auto and pen injectors, have been extensively utilized for the
administration of drugs to treat medical conditions ranging from cancer to
autoimmune disorders. The global market for injectable drug delivery devices
has witnessed continuously increasing R&D. As a result, the market is
fragmented into various high-end and technologically advanced products. Following
the illustrated course, it is projected that an increasing prevalence of
chronic diseases, growing adoption of self-injectable devices, and rising FDA
approvals drive the market growth. However, the presence of cross-contamination
and increasing cost of high-end products are estimated to restrain the market
growth during the forecast period.
Market Dynamics
The global injectable drug delivery
devices prevalence of chronic diseases such as diabetes, heart diseases,
multiple sclerosis, cancer, and arthritis have increased. According to the
statistical report published by the American Diabetes Association, in 2017,
~30.3 million, i.e., 9.4% of the total population within the US had diabetes in
2015. Moreover, the fact sheet of 2018 published by the World Health
Organization estimates cancer to be the second leading cause of death across
the globe. The disease is estimated to cause ~9.6 million deaths in 2018. The
other factors that are driving the global injectable drug delivery devices
market are growing adoption of self-injectable devices, Rising FDA approvals
for the drug delivery devices, and others.
Global Injectable
Drug Delivery Devices Industry Size, by Site of Delivery, 2017 &
2023 (USD Million)
Segmentation
The global Injectable drug delivery
devices market has been segmented into devices, therapeutic application,
usage pattern, site of delivery, distribution channel, and facility of use.
Based on device, the global market is
divided into conventional injection devices and self-injection devices.
Based on therapeutic application, the
global market is segmented into autoimmune diseases, hormonal disorders, and
cancer.
Based on usage pattern, the global market
is divided into curative pattern and immunization.
Based on site of delivery, the global
market is segmented into intramuscular, subcutaneous, and intradermal.
Based on distribution channel, the global
market is divided into hospital & retail pharmacies and online platforms.
Based on facility of use, the global
market is segmented into hospitals and clinics and home care settings.
Key Players
The prominent players in the
global Injectable drug delivery devices market are Eisai Co., Ltd, Antares Pharma, AstraZeneca,
Becton, Dickinson and Company, Eli Lilly and Company, F. Hoffmann-La Roche AG,
Johnson & Johnson Services Inc., Mylan N.V., Novartis AG, Novo Nordisk,
Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd, and Inovio
Pharmaceuticals Inc.
Regional Analysis
The global Injectable drug delivery
devices market, based on region, is segmented into the Americas, Europe,
Asia-Pacific, and the Middle East & Africa.
The Americas is anticipated to dominate
the global injectable drug delivery devices market owing to the rising
awareness about the condition and high healthcare expenditure. The region is
expected to reach USD 17,401.8 million by 2023 with a CAGR
of 11.3% from2018 to 2023. The Americas accounted largest
regional market owing to the growing biotechnology industry, the
ever-increasing prevalence of cancer and diabetes, and a well-developed
healthcare sector.
Europe accounted for the second-largest
market share in 2017 due to extensive R&D in healthcare,
increasing funding, and growing adoption of the devices within the region.
On the other hand, the Middle East &
Africa is expected to observe slow growth due to less exposure to healthcare
services, lack of awareness, and stringent government rules and regulations.
Browse More Medical Devices Reports @ https://www.marketresearchfuture.com/categories/medical-devices-market-report
No comments:
Post a Comment